Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
0.88 (1y: +59%)
Market Cap 34.6 M P/E(ttm)
Enterprise Value P/B
CPRX- NAS (USA)
Catalyst Pharmaceutical Partners, Inc.
Not Rated
Top Ranked Predictable Companies
$0.88
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
» CPRX's 10-Y Financials

Financials


» Details

Insider Trades

Latest Guru Trades with CPRX



No Insider Trades Found!

Top Ranked Articles about Catalyst Pharmaceutical Partners, Inc.

Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD
July 9, 2012
According to GuruFocus Insider Data, these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below: Read more...

Ratios

vs
industry		 vs
history

Valuation & Return

vs
industry		 vs
history

Business Description

Catalyst Pharmaceutical Partners, Inc. was incorporated in Delaware in July 2006. The Company is a development-stage specialty pharmaceutical Company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. It has two products in development. It is currently evaluating its lead drug candidate, CPP-109 (its formulation of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 and CPP-115 have both been granted 'Fast Track' status by the FDA for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 and CPP-115 are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. The Company is in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. It is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and other selected central nervous disease indications. The Company competes against pharmaceutical companies that are developing or currently marketing therapies for addictive substances. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:CN2.Germany
» More Articles for CPRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN Jun 04 2012 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 15 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Aug 12 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 9,359 Shares Jun 16 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) May 17 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 25,000 Shares Nov 16 2009 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 12 2009 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Aug 07 2009 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) May 13 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial
FEEDBACK